MedCity News

JUNE 16, 2023

The consensus is 2022 was a challenging year for digital health companies. billion in 2022 — down 56% from $40.2 billion in 2022 — down 56% from $40.2 Rather, 2022 represents an overdue correction in the midst of global economic uncertainty after a period of overexuberance and lofty expectations in digital health.

Pharma 113

Pharma Food and Drug Administration Recruitment Pharmacology 113

European Pharmaceutical Review

APRIL 13, 2023

Australia recently re-classified MDMA and psilocybin to allow prescription of MDMA for the treatment of post-traumatic stress disorder and psilocybin for treatment-resistant depression by psychiatrists. Pharmacological Reviews. World Health Organization; 2022 [cited 2023Mar]. References Nichols DE. Psychedelics.

Medicine 113

Medicine Food and Drug Administration Doctors Government 113

Pharmaceutical Technology

MARCH 17, 2023

Companies are testing the use of digital platforms along with pharmacological treatments. But while appealing, the prospects of developing a merged approach that combines both digital and pharmacological therapeutics remain challenging. Digital therapeutics can be also categorised based on their regulatory journey.

Prescription 111

Prescription Pharmacology Pharma Medical 111

Pharmaceutical Technology

AUGUST 8, 2022

There’s no dearth of interest, however, in applying digital solutions to healthcare. The digital pill, now marketed by Otsuka Pharmaceuticals, is forecasted to make $27 million in sales in 2022, as per GlobalData. It potentially helps individuals lend some kind of concrete evidence to discussions with their healthcare provider.

Food and Drug Administration 122

Food and Drug Administration FDA Medicine Patients 122